Smith & Nephew
This article was originally published in The Gray Sheet
Executive Summary
UK-based device manufacturer acquires Collagenase enzyme debrider product from BASF Pharma, the pharmaceutical arm of the German chemical maker BASF AG, for roughly $118 mil. ([L]74 mil.) in cash. The product, which cleanses and removes dead tissue from chronic wounds and burns, is sold under the brand name Santyl in North America and Iruxol and Novuxol outside North America. CEO Christopher Donnell reports Feb. 3 that the company plans to introduce the Dermagraft human dermal skin replacement for the treatment of hard-to-heal diabetic foot ulcers in the U.S. during the second half of 2000. Smith & Nephew also plans to launch a light-sensitive "ouchless" adhesive dressing in 2001 that would remove itself upon exposure to light, the exec notes
You may also be interested in...
ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated
Smith & Nephew's joint venture with Advanced Tissue Sciences to develop and market Dermagraft bio-engineered skin will be a major driver of S&N growth over the next five years, the British firm anticipates
ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated
Smith & Nephew's joint venture with Advanced Tissue Sciences to develop and market Dermagraft bio-engineered skin will be a major driver of S&N growth over the next five years, the British firm anticipates
Smith & Nephew Exogen 2000 Labeling For Non-Union Fracture Approved
Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.